PTO/SB/08A (08-00)

Approved for use through 10/31/2022, OMB 0661-0331
U.S. Petent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to respond to a cofection of fromtation unless it contains a valid OMB control number.

Substitute for form 1448A/PTO

SEP 1 2 2003

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete & Konsus			
Complete If Known Application Number 10/602,214			
Filing Date	6/24/03		
First Named Inventor	Quan et al.		
Group Art Unit	1624		
Examiner Name	Unknown T. TRUONS		
Attorney Docket Number	DM-6904 CNT 2		

				U.S. PATENT DOCUM	MENTS	chan subclass
Cumples		U.S. Peterni Doc	ument	Name of Patentas or Applicant		
Examiner initials •	Cite No.1	Number Kind (If knd	Code ² of Cited Document		Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
TNI	V	5,202,330	Α	E. R. Squibb & Sons, Inc.	4/13/1993	514/274
	/	5,317,103	Α	Merck Sharp & Dohrne Limited	5/31/1994	544/367
	<u></u>	5,342,851	Α	McNell-PPC, Inc.	8/30/1994	514/370
	0	5,463,071	Α	Dr. Karl Thomae GmbH	10/31/1995	548/287
	1	5,616,601	A	GD Searte & Co	4/1/1997	574 /399
	1	5,681,838	Α	i Hoechst AG	10/28/1897	514 /307
	1	5,707,998	A	; Eisai Co., Ltd.	1/13/1998	514/259
	0,	6,020,357 A		DuPont Pharma, ': Company	2/1/2000	514/406
M1	✓					· · · · · · · · · · · · · · · · ·

				FOREIG	N PATENT DOCU	MENTS		······································
Examiner	Cite	Foreign Patent Document i		Name of Patentee	Date of Publication of	Pagas, Columna, Lines,		
initials*	No.1	Office ³	Number ⁴	Kind Code ⁶ (<i>il known</i>)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T _a
TMT	√	wo	9402477	Ą	Merck Sharp & Dohme Limited	2/3/1994		
TM	<u>~</u>	wo	9514683	Ą	DuPont Merck Pharma. Company	6/1/1995		
1	\(\tag{\tau} \)	wo	9518111	A	DuPont Merck Pharma, Company	7/6/1995		
	V	wo	9628427	A	Bedex Lab., Inc.	9/19/1996		
	1	wo	9640143	A	SmithKline Beecham Corporation	12/19/1996		
	V ·	wo	9723212	A _i	DuPont Merck Pharma. Company	7/3/1997		
mq		wo	9732583	A.	SmithKline Beecham Corporation	8/12/1997		

Examiner Signature	Worn	Date Considered	7/28/05
EVALUATE LINE			

EXAMINER: Initial if reference considered, whether or not cliction is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to piace a check mark hee if English language Translation is attached.

1. **

work Reduction Act of 1956

Approved for use through 10/31/2022. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
persons are required to respond to a collection of information unless it contains a veril OMB control number.

SUBSTITUTE FOR THE STATEMENT BY APPLICANT

Compl te if Known

Application Number 10/602,214

Filing Date 6/24/03

First Named Inventor Quan tal.

Group Art Unit 1624

Examiner Name Unknown 72 TRUONGS

(use as many sheets as necessary)

2 of 2

Sheet

Attorney Docket Number DM-6904 CNT 2

					FOREIGI	N PATENT DOCU	MENTS		
-		04-	Foreign Patent Document		Name of Palentee	Date of Publication of	Pages, Columns, Lines, Where Relevant		
	niner Iala*	Cite No. ¹	Office ³	Number ⁴	Kind Cods ⁵ (If known)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	Te
71	M	V	EP	234830	A,	E. R. Squibb & Sons, Inc.	9/2/1987	<i>f</i>	
			EP	236902	A	E. R. Squibb & Sons, Inc.	9/16/1987		
		./	EP	513387	ξB	Otsuka Pharm. Co.	11/19/19 9 2		
			EP	554829	[{] A	Fujisawa Pharm. Co,	8/11/1993		,
17	K		JP	4247081	A	Takeda Chem. Ind. Ltd.	9/3/1992	Chemical Abstract	
<u> </u>					 				
-					1 7				
					4)				

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
TWI		NDWELL et al. "Diarylamidine derivatives with one or both of the any moleties consisting of an indole or indole- ike ring. Inhibitors of arginine-specific esteroproteases". J. Mad. Chem. (1978), 21(7), 613-623.					
		.1					
		į.					
		, ,					
		ę .					

	the same of the last of the same of the sa		
Examiner Signature	Moni	Date Considered	7/28/05

^{&#}x27;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE preons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PT

ease type a plus sign (+) inside this

SEP 1 2 2003

INFORMATION DESCLOSUSE STATEMENT BY AFFECTANT

(use as many sheets as necessary)

neet 1 of 2,

Complete if Known				
Application Alumban				
Application Number	10/602,214			
Filing Date	6/24/03			
First Named Inventor	Quan et al.			
Group Art Unit				
Examiner Name	Unknown			
Attorney Docket Number	DM-6904 CMT 2			

				U.S. PATENT DOCUM	MENTS	
		U.S. Patent Doc	ement	Name of Patentee or Applicant	Date of Publication et	Pages, Columns, Lines, Where Relevan
Examiner Initials *	Cite No.	Number Kind (if kno		of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
•		5,202,330	А	E. R. Squibb & Sons, Inc.	4/13/1993	
		5,317,103	А	Merck Sharp & Dohme Limited	5/31/1994	
		5,342,851	Α	McNeil-PPC, Inc.	8/30/1994	
,		5,463,071	Α	Dr. Karl Thomae GmbH	10/31/1995	
		5,616,601	Α	GD Searle & Co	4/1/1997	
		5,681,838	Α	Hoechst AG	10/28/1997	
		5,707,998	Α	Eisai Co., Ltd.	1/13/1998	
		6,020,357	Α	DuPopt Pharma. Company	2/1/2000	

,				FØREIGI	N PATENT DOCU	MENTS		
Examiner Initials*	Cite No.		eign Patent Docu	ment ind Code ⁵	Name of Patentee or Applicant of	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant	
1110013	140.	Office ³		if known)	Cited Document	MM-DD-YYYY	Passages or Relevant Figures Appear	To
		wo	9402477	Α	Merck Sharp & Dohme Limited	2/3/1994	*	
		·wo	9514683	А	DuPont Merck Pharma. Company	6/1/1995		•
		wo/	9518111	A	DuPont Merck Pharma. Company	7/6/1995		
		wo	9628427	Α	Berlex Lab., Inc.	9/19/1996		
		wo	9640143	A	SmithKline Beecham Corporation	12/19/1996		
·		wo	9723212	. А	DuPont Merck Pharma. Company	7/3/1997		•
	1	wo	9732583	Α	SmithKline Beecham Corporation	9/12/1997		

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

orlo

+

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁸ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PT

Sheet

INFORMATION BISC STATEMENT BY

(use as many sheets as necessary)

of 2 2

Complete if Known			
Application Number	10/602,214		
Filing Date	6/24/03		
First Named Inventor	Quan et al.		
Group Art Unit	1624		
Examiner Name	Unknown		
Attacker Decket Number	DM 6004 CNT 2		

				FOREIG	N PATENT DOCU	MENTS		
Ci	Cite No.	Foreign Patent Document			Name of Patentee	Date of Publication of	Pages, Columns, Lines,	
Examiner Initials*		Office ³	Number ⁴	Kind Code ⁵ (if known)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T ₆
		EP	234830	Α	E. R. Squibb & Sons, Inc.	9/2/1987		
		EP	236902	Α	E. R. Squibb & Sons, Inc.	9/16/1987		
		EP	513387	В	Otsuka Pharm. Co.	11/19/1992		
/		EP	554829	A	Fujisawa Pharm. Co.	8/11/1993		
/		JP	4247081	Α	Takeda Chem. Ind. Ltd.	9/3/1992	Chemical Abstract	
		 		<u> </u>	/			-
		 	ļ					
	<u> </u>	 						

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		TIDWELL et al. *Diarylamidine derivatives with one or both of the aryl moleties consisting of an indole- like ring inhibitors of arginine-specific esteroproteases*. J. Med. Chem. (1978), 21(7), 613-623.	

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this

U.S. Patent and Traden is are required to respond to a collection of info MAR 2 2 2002 B

PTO/SB/08A (08-00) Office: U.S. DEPARTMENT OF COMMERCE

09/924,381

8/8/2001

Lam et al.

Unknown

1624

or use through 10/31/2002. OMB 0651-0031 ation unless it contains a valid OMB control number Complete if Known

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPERDANTS

(use as many sheets as necessary)

Sheet 0

	necessary)	Evening
of	2	Examiner Name
-		Attorney Docket Number
_		

Application Number

First Named Inventor

Filing Date

Group Art Unit

Examiner	Cite	U.S. Patent Do	cument	U.S. PATENT DOCUMENTS					
Initials •	No.1	Number Kind Code ² (If known)		Name of Patentee or Applicant of Cited Document	Date of Publication of . Cited Document	Pages, Columns, Lines, Where Relevan			
TMI		5,202,330	A	E. R. Squibb & Sons,	MM-DD-YYYY	Passages or Relevant Clan Figures Appear Subb			
1		5,317,103	A	Inc. Merck Sharp & Dohme	4/13/1993	514/274			
++	_/.	5,342,851	A	Limited McNeil-PPC, Inc.	5/31/1994	544/367			
1		5,463,071	Α	Dr. Karl Thomae	8/30/1994	514/390			
+	/	5,616,601	A	GmbH GD Searle & Co	10/31/1995	548/251			
+-+	1	5,681,838	Α	Hoechst AG	4/1/1997	5/4/399			
n ar	-	5,707,998	_ A	Eisai Co., Ltd.	10/28/1997 1/13/1998	5/4 /309			
V	4	6,020,357	Α	DuPont Pharma. Company	2/1/2000	514 /259			

Exa	mine			Foreign Patent Do	FOREIC current	GN PATENT DOCL	MENTS		
	tials*	No.1	Office ³		Kind Code ⁵ (if known)	Name of Patentee or Applicant of . Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant	
11	NT	1	Wo	9402477	Α	Merck Sharp & Dohme Limited	2/3/1994	Passages or Relevant Figures Appear	T ₆
_	_	V	wo	9514683	А	DuPont Merck Pharma. Company	6/1/1995		
_		V	Wo	9518111	A	DuPont Merck Pharma. Company	7/6/1995		
\dashv		V	Wo	9628427	Α	Berlex Lab., Inc.	9/19/1996		
\dashv	4		wo	9640143	Α	SmithKline Beecham Corporation	12/19/1996		
4	1	V	Wo	9723212	A	DuPont Merck Pharma.	7/3/1997		
\mathcal{N}	1	/	WO	9732583	Ą	Company SmithKline Beecham Corporation	9/12/1997	-	

Corporation
Examiner
Signature
Date
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MEED considered. Include copy of this form with next communication
considered, include copy of this formation or not citation is in conference.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through dilation if not in conformance and not

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Unique citation designation number. See attached Kinds of U.S. Patent Documents, Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 If possible. * Applicant is to place a